Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-77242113 in Moderate to Severe Plaque Psoriasis
NCT06934226Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2025
- Primary completion
- Nov 2025
- Modality
- Peptides, Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial of icotrokinra in plaque psoriasis (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Investigator's Global Assessment Score of 0 or 1 and >= 2 Grade Improvement at 16 weeks and Psoriasis Area and Severity Index 90 Response at 28 weeks. Started Apr 2025; status: active, not recruiting.
02
Drugs
icotrokinra
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT06934226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06934226.